Transcranial direct current stimulation as a treatment option in CSWS-prelimi...Edina Timea Varga
Cathodal transcranial direct current stimulation was tested as a potential treatment for continuous spikes and waves during slow wave sleep in children. The study aimed to detect the effect of cathodal tDCS on epileptiform EEG discharges in three patients. Cathodal tDCS was applied at 1 mA for 20 minutes over the epileptic focus. While no effect was seen in two patients, spike wave activity disappeared after sham stimulation in one patient. Larger studies are still needed to reliably determine the efficacy of tDCS for treating continuous spikes and waves during slow wave sleep.
This document provides diagnostic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP), including:
1) Clinical criteria for typical and atypical CIDP with inclusion/exclusion factors.
2) Definite, probable, and possible electrophysiological criteria involving compound muscle action potential tests.
3) Supportive diagnostic criteria including cerebrospinal fluid analysis, MRI findings, nerve conduction studies, and nerve biopsy results.
It also outlines inclusion/exclusion criteria and supportive criteria specifically for diagnosing pure sensory CIDP without motor involvement.
The GBS|CIDP Foundation International has officially recognized Mr. Sait Mentes Birlik as a Liaison for the organization in Turkey. As a Liaison, Mr. Birlik will represent the Foundation by conducting patient visitations in hospitals and raising awareness and support for Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and related conditions. The GBS|CIDP Foundation International is a global non-profit organization founded in 1980 to support individuals affected by GBS, CIDP, and related syndromes through programs focused on support, education, research, and advocacy.
Global Intravenous Immunoglobulin Market (By Application, Types and Geography...Allied Market Research
IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.
This document summarizes information presented at a conference on immune-mediated neuropathies and treatment options for patients who do not respond to conventional therapies. It discusses various subtypes of chronic inflammatory demyelinating polyneuropathy (CIDP) and provides treatment guidelines. For patients who do not respond initially, it recommends reconsidering the diagnosis or trying immunosuppressant drugs, and more research is needed to determine their effectiveness for CIDP.
This document summarizes key information about Guillain-Barré syndrome (GBS) and related acute inflammatory neuropathies. It describes the incidence and subtypes of GBS, including typical symptoms such as weakness and sensory disturbances. Electrodiagnostic findings are outlined, including conduction block, prolonged distal latencies, and reduced nerve conduction velocities supportive of demyelination. The time course of GBS and potential etiologies like infection are mentioned. Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy are also summarized, with details on clinical features and electrodiagnostic patterns that help differentiate these conditions from GBS.
This document provides an overview of peripheral neuropathy, including:
1. It describes the anatomy of peripheral nerves and different types of peripheral neuropathies such as mononeuropathy, mononeuropathy multiplex, polyneuropathy, polyradiculopathy, and plexopathy.
2. It outlines the various clinical presentations of peripheral neuropathy including sensory, motor, and autonomic symptoms as well as patterns of nerve fiber involvement.
3. It discusses the etiology, clinical course, investigations and management of different peripheral neuropathies.
CIDP is a chronic acquired demyelinating neuropathy. It has two patterns - a continuous progressive course over months to years or a relapsing course with partial recovery between episodes. Diagnosis requires documentation of demyelination through electrodiagnostic testing, CSF analysis and sometimes nerve biopsy. Treatment includes corticosteroids, IVIG and plasmapheresis, which are effective in around 50-70% of patients. Corticosteroids are usually the first line treatment, starting with high dose prednisone and slowly tapering as response occurs.
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...Reports Corner
GBI Research's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan.
https://www.reportscorner.com/reports/20855/Immunoglobulins-Market-to-2019---Demand-in-Primary-Immunodeficiency-(PI)-and-Chronic-Inflammatory-Demyelinating-Polyneuropathy-(CIDP)-Potentially-Supplemented-by-Approvals-for-Alzheimers-Disease/
Competitive Intelligence to Decision Pattern by Elijah EzenduElijah Ezendu
Competitive Intelligence to Decision Pattern (CIDP) is a method of rating Corporate Competitive Intelligence Operations through patterns of systemic flow from Competitive Intelligence to Decision, thereby providing appropriate classification ranging from AAAAAAAA to DDDDDDDD.
Therapeutic apheresis involves separating blood components outside the body to remove substances causing disease symptoms. There are two main types: donor apheresis produces blood components, while therapeutic apheresis treats diseases by removing toxins, antibodies, lipids, etc. from the blood. Therapeutic plasma exchange is commonly used to treat various autoimmune and inflammatory conditions by removing pathogenic substances from plasma. Guidelines provide evidence-based recommendations on appropriate uses of therapeutic apheresis. Conditions like Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis often respond well to therapeutic apheresis.
This document describes a case of a 32-year-old male who presented with weakness in all four limbs that progressed over a week. Based on examination and investigations, he was diagnosed with recurrent quadriparesis likely due to an autoimmune etiology of chronic inflammatory demyelinating polyneuropathy (CIDP) associated with systemic lupus erythematosus (SLE). He showed improvement in symptoms with intravenous steroids and plasma exchange.
This document provides information about chronic inflammatory demyelinating polyneuropathy (CIDP), including:
1) CIDP is an autoimmune disorder where the immune system attacks the peripheral nervous system, specifically targeting the myelin insulation around nerves.
2) Symptoms include numbness, tingling, muscle weakness, loss of reflexes, and abnormal sensations that typically start distally and progress proximally.
3) Diagnosis involves nerve conduction studies showing signs of demyelination in multiple nerves as well as EMG findings such as prolonged latencies and conduction blocks. Nerve biopsy may also show signs of inflammation and demyelination.
Transcranial direct current stimulation as a treatment option in CSWS-prelimi...Edina Timea Varga
Cathodal transcranial direct current stimulation was tested as a potential treatment for continuous spikes and waves during slow wave sleep in children. The study aimed to detect the effect of cathodal tDCS on epileptiform EEG discharges in three patients. Cathodal tDCS was applied at 1 mA for 20 minutes over the epileptic focus. While no effect was seen in two patients, spike wave activity disappeared after sham stimulation in one patient. Larger studies are still needed to reliably determine the efficacy of tDCS for treating continuous spikes and waves during slow wave sleep.
This document provides diagnostic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP), including:
1) Clinical criteria for typical and atypical CIDP with inclusion/exclusion factors.
2) Definite, probable, and possible electrophysiological criteria involving compound muscle action potential tests.
3) Supportive diagnostic criteria including cerebrospinal fluid analysis, MRI findings, nerve conduction studies, and nerve biopsy results.
It also outlines inclusion/exclusion criteria and supportive criteria specifically for diagnosing pure sensory CIDP without motor involvement.
The GBS|CIDP Foundation International has officially recognized Mr. Sait Mentes Birlik as a Liaison for the organization in Turkey. As a Liaison, Mr. Birlik will represent the Foundation by conducting patient visitations in hospitals and raising awareness and support for Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and related conditions. The GBS|CIDP Foundation International is a global non-profit organization founded in 1980 to support individuals affected by GBS, CIDP, and related syndromes through programs focused on support, education, research, and advocacy.
Global Intravenous Immunoglobulin Market (By Application, Types and Geography...Allied Market Research
IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.
This document summarizes information presented at a conference on immune-mediated neuropathies and treatment options for patients who do not respond to conventional therapies. It discusses various subtypes of chronic inflammatory demyelinating polyneuropathy (CIDP) and provides treatment guidelines. For patients who do not respond initially, it recommends reconsidering the diagnosis or trying immunosuppressant drugs, and more research is needed to determine their effectiveness for CIDP.
This document summarizes key information about Guillain-Barré syndrome (GBS) and related acute inflammatory neuropathies. It describes the incidence and subtypes of GBS, including typical symptoms such as weakness and sensory disturbances. Electrodiagnostic findings are outlined, including conduction block, prolonged distal latencies, and reduced nerve conduction velocities supportive of demyelination. The time course of GBS and potential etiologies like infection are mentioned. Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy are also summarized, with details on clinical features and electrodiagnostic patterns that help differentiate these conditions from GBS.
This document provides an overview of peripheral neuropathy, including:
1. It describes the anatomy of peripheral nerves and different types of peripheral neuropathies such as mononeuropathy, mononeuropathy multiplex, polyneuropathy, polyradiculopathy, and plexopathy.
2. It outlines the various clinical presentations of peripheral neuropathy including sensory, motor, and autonomic symptoms as well as patterns of nerve fiber involvement.
3. It discusses the etiology, clinical course, investigations and management of different peripheral neuropathies.
CIDP is a chronic acquired demyelinating neuropathy. It has two patterns - a continuous progressive course over months to years or a relapsing course with partial recovery between episodes. Diagnosis requires documentation of demyelination through electrodiagnostic testing, CSF analysis and sometimes nerve biopsy. Treatment includes corticosteroids, IVIG and plasmapheresis, which are effective in around 50-70% of patients. Corticosteroids are usually the first line treatment, starting with high dose prednisone and slowly tapering as response occurs.
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...Reports Corner
GBI Research's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan.
https://www.reportscorner.com/reports/20855/Immunoglobulins-Market-to-2019---Demand-in-Primary-Immunodeficiency-(PI)-and-Chronic-Inflammatory-Demyelinating-Polyneuropathy-(CIDP)-Potentially-Supplemented-by-Approvals-for-Alzheimers-Disease/
Competitive Intelligence to Decision Pattern by Elijah EzenduElijah Ezendu
Competitive Intelligence to Decision Pattern (CIDP) is a method of rating Corporate Competitive Intelligence Operations through patterns of systemic flow from Competitive Intelligence to Decision, thereby providing appropriate classification ranging from AAAAAAAA to DDDDDDDD.
Therapeutic apheresis involves separating blood components outside the body to remove substances causing disease symptoms. There are two main types: donor apheresis produces blood components, while therapeutic apheresis treats diseases by removing toxins, antibodies, lipids, etc. from the blood. Therapeutic plasma exchange is commonly used to treat various autoimmune and inflammatory conditions by removing pathogenic substances from plasma. Guidelines provide evidence-based recommendations on appropriate uses of therapeutic apheresis. Conditions like Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis often respond well to therapeutic apheresis.
This document describes a case of a 32-year-old male who presented with weakness in all four limbs that progressed over a week. Based on examination and investigations, he was diagnosed with recurrent quadriparesis likely due to an autoimmune etiology of chronic inflammatory demyelinating polyneuropathy (CIDP) associated with systemic lupus erythematosus (SLE). He showed improvement in symptoms with intravenous steroids and plasma exchange.
This document provides information about chronic inflammatory demyelinating polyneuropathy (CIDP), including:
1) CIDP is an autoimmune disorder where the immune system attacks the peripheral nervous system, specifically targeting the myelin insulation around nerves.
2) Symptoms include numbness, tingling, muscle weakness, loss of reflexes, and abnormal sensations that typically start distally and progress proximally.
3) Diagnosis involves nerve conduction studies showing signs of demyelination in multiple nerves as well as EMG findings such as prolonged latencies and conduction blocks. Nerve biopsy may also show signs of inflammation and demyelination.
Early resuscitation, chest compression, defibrillation in crutial to a successful postresuscitation phase and recovery. Basic and advanced life support.
Epileptic sizure can either be presented due to epilepsy or non-epiletic origin. DIfferential diagnosis is crutial in oder to rovide proper treatment for patients.
Botulinum toxin treatment of focal dystonia: writer’s cramp. Case report.Edina Timea Varga
Botulinum toxin treatment with EMG and ultrasound guidance for focal and segmental dystonia. Writer's cramp can be an initial part of segmental dystonia as well.
Interval treatment of migraine with botulinum toxinEdina Timea Varga
How to treat chonic migraine and reduce headache frequency and duration? Take a look into the botulinum toxin injection treatment for chronic migraine patients!
Seminar on clinical neurophysiology for medical students 2018.
Neurophysiological follow-up of IVIG treatment in CIDP
1. CIDP Intravénás Immunglobulin kezelésének
neurofiziológiai nyomonkövetése –
Irodalmi áttekintés és saját anyag
Dr. Varga Edina Tímea
Szegedi Tudományegyetem,
Neurológiai Klinika
MANIT IV. Kongresszusa
Visegrád, 2017. szeptember 29.
www.varganeuro.com
3. CIDP
Hickman et al. Neuro-Ophtalmology 2013;37(4):146-156
Journal of the Peripheral Nervous System 15:1–9 (2010)
Ripellino et al. Autoimmune Diseases
Vol 2014, Article ID 201657, p11)
J Korean Med Sci. 2010 Jul;25(7):1101-1104.
Krónikus: > két hónapja (kórtörténet)
Immunmediált: celluláris és humorális immunválasz (CSF, biopszia)
Demyelinizációs: myelinhüvely károsodás (ENG – biopszia)
Polyradiculoneuropáthia: közel szimmetrikus, több perifériás ideg
Spektrum betegség:
Kórlefolyás egyéni: egyfázisú progresszív (2/3)
relapszáló forma
Érintett: motoros szenzoros ideg is
Proximális érintettség: SEP, MRI
Neuro-ophtalmologiai érintettség – VEP, MRI
Terápiás válasz is egyéni
Követése??
4. CIDP klinikai követése
INCAT skála
Hughes skála
Maximális kéz szorítóerő vizsgálat
MRC összesített pontérték (8 izom)
Rasch-built Overall Disability Scale (R-ODS)
Neurofiziológiai vizsgálatok: ENG, EMG, SEP, VEP
Neuroradiológia (MRI, UH)
Ripellino et al. Autoimmune Diseases
Volume 2014, Article ID 201657, 11 pages
Van Nes SI et al. Neurology 2011 Jan 25;76(4):337-45
Hickman et al. Neuro-Ophtalmology 2013;37(4):146-156
Journal of the Peripheral Nervous System 15:1–9 (2010)
J Neurol Neurosurg Psychiatry 2002;72:596–601
5. CIDP klinikai követése
Hickman et al. Neuro-Ophtalmology 2013;37(4):146-156
Journal of the Peripheral Nervous System 15:1–9 (2010)
http://farmacologiaclinica.info/scales/overall-disability-sum-score/
7. CIDP klinikai követése
INCAT skála
Maximális kéz szorítóerő vizsgálat
MRC összesített pontérték (8 izom)
Rasch-built Overall Disability Scale (R-ODS)
Neurofiziológiai vizsgálatok
Neuroradiológia (MRI, UH)
EFNS/PNS CIDP GUIDELINES
Journal of the Peripheral Nervous System 15:1–9 (2010
Ripellino et al. Autoimmune Diseases
Volume 2014, Article ID 201657, 11 pages)
8. American Academy of Neurology Ad Hoc Subcommittee Electrodiagnostic Criteria for chronic inflammatory demyelinating
polyneuropathy [Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. (1991).].
motoros idegek>75%-ban regisztrálható válasz
10. CIDP Criteria Working Group
150 CIDP beteg retrospektív elemzés
klinikum NF, diff.dg. kizárások alapján
117 betegnél validálták
Korábban AAN alapján dg.
40 CIDP beteg közül:
63%: klinikum és NF is
20% csak klinikai kritériumok
18%: csak NF feltételek
sok betegnél már kiesett válaszAAN-nek nem felel meg
(motoros idegek>75%-ban regisztrálható válasz)
Koski et al. J Neurol Sciences 277 (2009):1-8.
Krónikus (>8 hete), progresszív
Nem genetikus
Nincs paraproteinaemia
Alábbiak közül egy:
NF: idegek>75%-ában van válasz, és idegek >50%:ban:DL VAGY VS VAGY F-latencia
Motoros tünetek szimmetrikus kezdete, mind a 4 végtag szimmetrikus gyengesége és >1
végtagban proximalis gyengeség
Szenzitivitás 83%
Specificiás 97%
15. AAN vs EFNS/PNS
Journal of the Peripheral Nervous System 15:1–9 (2010)
Az AAN kritériumrendszere megengedőbb: nem kötelező a
proximális, vagy a szimmetrikus gyengeség sem.
16. Probléma:
Legtöbb vizsgálat
AAN kritériumokon alapul (1991)
Betegek 50-60%-a teljesíti
Újabb kritériumrendszerek: 15 különböző EMG feltétel
Szenzitivitás, specificitás ?
EFNS/PNS és Koski
17. 11 beteg követése félévente, 1 éven keresztül (3 mérés)
Szign. csökkenés a kondukciós blokk gyakoriságában: 61%39% (p<0.01)
Zajló axonvesztés csökken (kezelés előtti sp. aktivitás:, 47%; 1 év után: 29%, P<0.01)
Szign. javulás a szenzoros ideg amplitudóban: 90%-ban érintett ideg 62% (p<0.01)
KONKLÚZIÓ:
Hosszútávú fenntartó IVIG kezelés javítja a CIDP betegek NF paramétereit, habár:
a betegek „IVIG-függők” maradnak
újabb kondukciós blokkok alakulhatnak ki
Clin Neurophysiol. 2007 Sep;118(9):1980-4. Epub 2007 Jun 28.
18. 21 CIDP beteg (EFNS/PNS)
3-6 hetente 1 g/ttkg IVIG
2 éven át évente (alap, 12. és 24. hó) NF mérések:
mko. n. suralis, n. tibialis, n. medinaus ENG (jobban érintett
oldali eredmények), 36 C bőrhőm.
2 éven át évente klinikum felmérése:
INCAT skála
Hughes skála
3 havonta revideálták az IVIG adagjt és a kezelés gyakoriságát
22. KONKLÚZIÓ:
IVIG az elsődlegesen választandó kezelés CIDP-ben
Klinikai skála és NF mérés együtt értékelendő, bár az ENG
eredmények stagnálása mellett a Hughes skálán javulás!
Hughes skála érzékenyebb, mint INCAT
IVIG adásának gyakoriságát és a gyógyszer adagját a klinikum és
a NF eredmények alapján határozzák meg.
23. IVIG adásának gyakoriságát és a gyógyszer adagját a klinikum és a NF
eredmények alapján határozzák meg. Adagot emeltek 15-20%-kal, ha:
klinikum (INCAT, Hughes) alapján objektivizálható volt a progresszió VAGY
CMAP amplitudó>1 mV
mDL>1 ms-kal
VS és F-latencia>20%-kal
24. Kuwabara S, et al. J Neurol Neurosurg Psychiatry 2017;0:1–7. doi:10.1136/jnnp-2017-316427
49 japán centrum
Fázis III.
49 beteg (EFNS/PNS)
Indukciós IVIG kezelés: 0.4 g/ttkg/nap 5 egymás utáni napon
Fenntartó: 3 hetente 1 g/ttkg
ENG: 1; 4; 28; 52. hét
Elsődleges végpontok (INCAT, ISS, kéz szorítóerő, MRC):
kezelésre reagáló betegek aránya 28. héten
relapszus aránya az 52. héten
26. Eredmények, konklúzió
kezelésre reagáló betegek aránya 28. héten: 77.6% (mind a 38-an folytatták)
relapszus aránya az 52. héten: a 38 beteg 10.5%-ban
összes (49) beteg 69.4%-a javult az egy év során
52 hetes kezelés hatásos a típusos CIDP esetekben a relapszus megelőzésére
Thrombotikus események előfordulásának esélye fennáll, ezt monitorozni kell
NF??
Kuwabara S, et al. J Neurol Neurosurg Psychiatry 2017;0:1–7. doi:10.1136/jnnp-2017-316427
27. SZTE Neurológiai Klinika CIDP betegek IVIG
kezelésének NF követése
Jelenleg SZTE: 22 beteg
kezdő adag: 0.4 g/ttkg 5 napon át
Fenntartó adag 1 g/ttkg
Max. finanszírozott fenntartó adag: 80 g
Dr. Dézsi Lívia, Dr. Horváth Zoltán
Berencsi Krisztina, Molnár Rózsa,
Hevesi Anita, Fülöp Beáta
28. SZTE Neurológiai Klinika CIDP betegek IVIG
kezelésének NF követése
• Vizsgálatba vont betegek:
Igazolt CIDP (EFNS/PNS)
IVIG kezelés
Legalább 5 éves EF követés, ill. min 4 EF mérés (Nihon Kohden Neuropack 4 csat.)
DM, pajzsmirigy betegség nincs.
8 beteget sikerült beválasztani
5 férfi / 3 nő,
aktuális átlag életkor : 67,4 év
Dr. Dézsi Lívia, Dr. Horváth Zoltán
Berencsi Krisztina, Molnár Rózsa,
Hevesi Anita, Fülöp Beáta
29.
30.
31.
32. Megjegyzés
Az évek során tapasztalható változást paraméterenként és idegenként
is más-más faktorok is befolyásolják: alagút szindrómák, diabetes,
porckorong betegség, metodikai hibák
A változás feltehetően nem lineáris
A betegség kezdeti szakasza nincs megfigyelve (első NF időpontja)
A súlyos állapot: kiesett EF értékek (tűelektródás ENG vagy EMG?)
Kevés adat, kevés beteg + nagy egyéni és betegek közötti szórás
34. Összefoglalás:
CIDP lassan progrediáló immunmediált polyneuropathia, mely
progresszió kezeléssel lassítható.
A 1-2 éves időtartam alatt NF módszerekkel a legtöbb NF
paraméterben stagnálását figyeltünk meg meg, de hosszabb távon
fokozatos romlás azonosítható.
35. Összefoglalás:
CIDP lassan progrediáló immunmediált polyneuropathia, mely
progresszió kezeléssel lassítható.
A 1-2 éves időtartam alatt NF módszerekkel a legtöbb NF
paraméterben stagnálását figyeltünk meg meg, de hosszabb távon
fokozatos romlás azonosítható.
CIDP variánsok, egyéb PNP - differenciál diagnosztika?
Betegség természetes lefolyása - fluktuáció
Komorbiditás kialakulása (infekció, CTS, DM!...)
Esetleg subdosisban adott gyógyszer miatt?
36. Összefoglalás:
CIDP lassan progrediáló immunmediált polyneuropathia, mely
progresszió kezeléssel lassítható.
A 1-2 éves időtartam alatt NF módszerekkel a legtöbb NF
paraméterben stagnálását figyeltük meg, de hosszabb távon fokozatos
romlás azonosítható.
Rendszeres NF kontroll segíthet a betegség lefolyásának ütemének
követésében.
37. Összefoglalás:
CIDP lassan progrediáló, immunmediált polyneuropathia, mely progresszió kezeléssel
lassítható.
A 1-2 éves időtartam alatt NF módszerekkel a legtöbb NF paraméterben stagnálását
figyeltük meg, de hosszabb távon fokozatos romlás azonosítható.
Rendszeres NF kontroll segíthet a betegség lefolyásának ütemének követésében.
Milyen rendszeres NF kontroll?
Mennyivel az IVIG beadása után?
Hány ideget vizsgáljunk?
Ahol korábban kiesett a válasz? – ENG, tűregisztráció, EMG, mennyire prox. legyen az ingerlés
Terápia meghatározására is alkalmas a NF mérés?
Klinikai skála és NF mérések együttes elemzése!
38. randomizált, placebo-kontrollált,
kettősvak, paralell-csoport vizsgálat
30 (23) CIDP beteg SCIG kezelése előtt és
12 hét után
ENG egy peroneus, medianus, ulnaris
idegen (DML, mCV, CMAP: ampl, tartam,
F-latencia)
QEMG (m. APB): MUNIX, MUSIX
Eredmény:
MUNIX érték SCIG csoport>placebo
(p<0,05)
MUSIX nem változott sem a kezelt,
sem a placebo csoportban
CMAP ampl. nőtt (p=0,05) a SCIG
csoportban
DML, mCV, F-latencia nem változott
Dán CIDP és MMN Csoport
39. A CIDP Intravénás Immunglobulin kezelésének
neurofiziológiai nyomonkövetésének
nehézségei –
Irodalmi áttekintés; saját anyagunk hibái
Dr. Varga Edina Tímea
Szegedi Tudományegyetem,
Neurológiai Klinika
MANIT IV. Kongresszusa
Visegrád, 2017. szeptember 29.